Dong Yunxia, Yu Chuwei, Ma Ningning, Xu Xiaoding, Wu Qian, Lu Henglei, Gong Likun, Chen Jing, Ren Jin
Center for Drug Safety Evaluation and Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai, 201203, China.
University of Chinese Academy of Sciences, No.19A Yuquan Road, Beijing, 100049, China.
Mol Biomed. 2022 Aug 10;3(1):25. doi: 10.1186/s43556-022-00089-w.
Lipotoxicity induced by the overload of lipid in the liver, especially excess free cholesterol (FC), has been recognized as one of driving factors in the transition from non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH). MicroRNA (miR)-379-5p has been reported to play regulatory roles in hepatic triglyceride homeostasis, but the relationship of miR-379-5p and hepatic cholesterol homeostasis has never been touched. In the current study, we found that hepatic miR-379-5p levels were decreased obviously in NAFLD patients and model mice compared with their controls. Moreover, miR-379-5p was discovered to be able to inhibit intracellular FC accumulation and alleviate mitochondrial damage induced by palmitic acid (PA) in vitro. Furthermore, overexpression of miR-379-5p in HFHC-fed db/db mice could reduce the level of hepatic total cholesterol (TC) and FC, and ameliorate hepatic injury reflected by the lower serum alanine aminotransferase (ALT) and aspartate transaminase (AST). Subsequently, by combining spectrometry (MS) and luciferase assay, we identified miR-379-5p suppressed STAT1 through transcriptional and translational regulation. Finally, we confirmed that STAT1 was a transcriptional factor of HMGCS1. In conclusion, miR-379-5p inhibits STAT1 expression and regulates cholesterol metabolism through the STAT1/HMGCS1 axis, suggesting miR-379-5p might be applied to improve lipotoxicity in the future.
肝脏中脂质过载,尤其是游离胆固醇(FC)过量所诱导的脂毒性,已被认为是非酒精性脂肪肝(NAFL)向非酒精性脂肪性肝炎(NASH)转变的驱动因素之一。据报道,微小RNA(miR)-379-5p在肝脏甘油三酯稳态中发挥调节作用,但miR-379-5p与肝脏胆固醇稳态的关系尚未涉及。在本研究中,我们发现与对照组相比,NAFLD患者和模型小鼠的肝脏miR-379-5p水平明显降低。此外,发现miR-379-5p能够在体外抑制细胞内FC积累,并减轻棕榈酸(PA)诱导的线粒体损伤。此外,在高脂高胆固醇饮食喂养的db/db小鼠中过表达miR-379-5p可降低肝脏总胆固醇(TC)和FC水平,并改善由较低血清丙氨酸氨基转移酶(ALT)和天冬氨酸氨基转移酶(AST)所反映的肝损伤。随后,通过结合质谱(MS)和荧光素酶测定,我们确定miR-379-5p通过转录和翻译调控抑制信号转导和转录激活因子1(STAT1)。最后,我们证实STAT1是3-羟基-3-甲基戊二酰辅酶A合酶1(HMGCS1)的转录因子。总之,miR-379-5p通过STAT1/HMGCS1轴抑制STAT1表达并调节胆固醇代谢,提示miR-379-5p未来可能用于改善脂毒性。